LUMO (Lumos Therapeutics) Earnings growth in current year

LUMO (Lumos Therapeutics) - company brandmark

Lumos Pharma, Inc. (LUMO) is developing a high-demand oral therapy for the treatment of growth hormone deficiency in children. Annual EPS progress confirms the asset's market potential, while 15.20 reflects the metric's baseline. However, geopolitical tensions are slowing international trials, and the company's environmental policy is limited to strict compliance with FDA regulations on biomaterial disposal.

LUMO: Lumos Pharma, Inc. Earnings per share growth in current year 07/04/2022 - 12/21/2024

Financial and market metric breakdowns for Lumos Pharma Inc (LUMO)

- share price and expert price forecast:
- business market valuation indicators:
Basic company analysis:LUMO - Lumos Therapeutics
Finished products of Lumos Pharma

The analyst assesses business resilience through profit dynamics, which determine the company's ability to weather market downturns. Effective distribution of rare metabolic drugs and the diversification of hubs ensure high margins for Lumos Pharma, Inc. (LUMO). The relative annual growth in net income per share measures the percentage change in EPS compared to the previous period, allowing the investor to evaluate the asset's fundamental value and the risks of capital freeze.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Altimmune Corp - Net earnings per one share growth for the current year|Aardvark Therapeutics Inc (AARD) - Earnings per share growth in current year|Net earnings per share change in current year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth in current year|Net earnings per share growth this year Biomea Fusion (BMEA)|Earnings growth in current year QNCX|Net earnings per one share growth for the current year GUTS|Earnings growth in current year VTVT (vTv Therapeutics Inc.)|Earnings per share increase in current year ATPC|Pluristem Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year synlogictx.com SYBX|LPCN: Earnings growth in current year|Matinas BioPharma Holdings, Inc. - Earnings per share increase in current year|SPRB (Spruce Biosciences Inc.) - Earnings growth in current year|galecto.com (GLTO) - Expected net earnings per share growth this year|Earnings per share growth in current year Carmell Therapeutics (CTCX)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year